Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04756401 · OUTCOME

Time to Response

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma · Source last updated 2026-09-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
Full Range
Time frame
2 years

What was measured

Time to response (TTR) is defined as time from the date of registration to the date of confirmed response using IMWG criteria. TTR will be summarized descriptively (median, range).

Analysis population: Only patients with a confirmed response are included in analysis

Groups in this outcome

Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)

Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\> \> Carfilzomib: Given IV\> \> Daratumumab: Given IV\> \> Dexamethasone: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> Selinexor: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)6

Reported measurements

Source class 1
Values in days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)34Not reported3085Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        30
        upper Limit
        85
        value
        34
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Time to response (TTR) is defined as time from the date of registration to the date of confirmed response using IMWG criteria. TTR will be summarized descriptively (median, range).
dispersion Type
Full Range
groups
  1. description
    Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\> \> Carfilzomib: Given IV\> \> Daratumumab: Given IV\> \> Dexamethasone: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> Selinexor: Given PO
    id
    OG000
    title
    Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)
param Type
MEDIAN
population Description
Only patients with a confirmed response are included in analysis
reporting Status
POSTED
time Frame
2 years
title
Time to Response
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice